Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback;